Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 5;8(6):807.
doi: 10.3390/jcm8060807.

Safety and Efficacy of Medical Cannabis in Fibromyalgia

Free PMC article

Safety and Efficacy of Medical Cannabis in Fibromyalgia

Iftach Sagy et al. J Clin Med. .
Free PMC article


Background: Chronic pain may be treated by medical cannabis. Yet, there is scarce evidence to support the role of medical cannabis in the treatment of fibromyalgia. The aim of the study was to investigate the characteristics, safety, and effectiveness of medical cannabis therapy for fibromyalgia.

Methods: A prospective observational study with six months follow-up period based on fibromyalgia patients who were willing to answer questionnaire in a specialized medical cannabis clinic between 2015 and 2017.

Results: Among the 367 fibromyalgia patients, the mean age was 52.9 ± 15.1, of whom 301 (82.0%) were women. Twenty eight patients (7.6%) stopped the treatment prior to the six months follow-up. The six months response rate was 70.8%. Pain intensity (scale 0-10) reduced from a median of 9.0 at baseline to 5.0 (p < 0.001), and 194 patients (81.1%) achieved treatment response. In a multivariate analysis, age above 60 years (odds ratio [OR] 0.34, 95% C.I 0.16-0.72), concerns about cannabis treatment (OR 0.36, 95% C.I 0.16-0.80), spasticity (OR 2.26, 95% C.I 1.08-4.72), and previous use of cannabis (OR 2.46 95% C.I 1.06-5.74) were associated with treatment outcome. The most common adverse effects were mild and included dizziness (7.9%), dry mouth (6.7%), and gastrointestinal symptoms (5.4%).

Conclusion: Medical cannabis appears to be a safe and effective alternative for the treatment of fibromyalgia symptoms. Standardization of treatment compounds and regimens are required.

Keywords: chronic pain; fibromyalgia; medical cannabis; quality of life.

Conflict of interest statement

The authors declare no conflict of interest.


Figure 1
Figure 1
Flow chart of the study population.
Figure 2
Figure 2
Perception of the general effect of cannabis on the patient’s condition after six months of treatment.
Figure 3
Figure 3
Assessment of the pain intensity on the 0–10 scale before and after six months of cannabis therapy (p < 0.001).
Figure 4
Figure 4
Quality of life prior and six months after the initiation of cannabis treatment (p < 0.001).

Similar articles

See all similar articles

Cited by 3 articles


    1. Phillips K., Clauw D.J. Central pain mechanisms in the rheumatic diseases: Future directions. Arthritis Rheumatol. 2013;65:291–302. doi: 10.1002/art.37739. - DOI - PMC - PubMed
    1. Aaron L.A., Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann. Intern. Med. 2001;134:868–881. doi: 10.7326/0003-4819-134-9_Part_2-200105011-00011. - DOI - PubMed
    1. Vincent A., Lahr B.D., Wolfe F., Clauw D.J., Whipple M.O., Oh T.H., Barton D.L., St. Sauver J. Prevalence of fibromyalgia: A population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res. 2013;65:786–792. doi: 10.1002/acr.21896. - DOI - PMC - PubMed
    1. Wolfe F., Ross K., Anderson J., Russell I.J., Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheumatol. 1995;38:19–28. doi: 10.1002/art.1780380104. - DOI - PubMed
    1. Macfarlane G.J., Kronisch C., Dean L.E., Atzeni F., Häuser W., Fluß E., Choy E., Kosek E., Amris K., Branco J., et al. EULAR revised recommendations for the management of fibromyalgia. Ann. Rheum. Dis. 2017;76:318–328. doi: 10.1136/annrheumdis-2016-209724. - DOI - PubMed